Sun, Dec 21, 2014, 12:35 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Sarepta Therapeutics, Inc. Message Board

  • system_architect_enterprise system_architect_enterprise Mar 21, 2013 8:17 AM Flag

    Buyout would need to be $100+ (worth $190-$380/share) math attached

    Eteplirsen could be a $500M annual product (based on 2,000 patients). The $500M figure comes from TheStreet, so you know how reliable that number is... That article goes on to e plain that the 2,000 patients could grow to 7,000 within 4 years, and even then is only 1/4 of the addressable market.

    Anyway. At $500M/year that figures to be based on 26M shares, revenue of about $19.23/share (round down to $19). Even with an ultra-conservative PE ratio of 10 that puts valuation around $190/share. At a PE of 20 (which is more appropriate given a projected growth from 2K patients to 7K (annualized growth of more than (50% so you could argue a PE of up to 50) but at a PE of 20 that values shares at $380/share.

    Therefore any buyout would have to be well over $100/share otherwise shareholders would be better served to wait it out & stay independent.

    DNDN math: at 50% year over Yale growth, and potentially a market of 28,000 patients (14x the original 2,000 number) you could argue the $500M= $19/share *14 = $266/share @ PE of 50 = $13,300/share.
    Just to show how ridiculous it can get.

    Still $100+ is very reasonable for a buyout.

 
SRPT
13.21-0.59(-4.28%)Dec 19 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.